Related Experiment Videos
Elevated carboxyhemoglobin associated with sodium nitroprusside treatment
Jesús López-Herce1, Raúl Borrego, Amaya Bustinza
1Pediatric Critical Care Unit, Gregorio Marañón University Hospital, Dr. Castelo 47, 28009 Madrid, Spain. pielvi@ya.com
Intensive Care Medicine
|July 26, 2005
Summary
High doses of sodium nitroprusside can cause carboxyhemoglobinemia in pediatric heart transplant patients. This condition, characterized by elevated carboxyhemoglobin levels, may lead to severe outcomes, necessitating careful monitoring.
Area of Science:
- Pediatric Cardiology
- Pharmacology
- Toxicology
Background:
- Sodium nitroprusside is a potent vasodilator used in critical care.
- Cardiac transplant recipients, particularly children, require careful hemodynamic management.
- Potential adverse effects of medications in pediatric populations warrant thorough investigation.
Observation:
- Four pediatric patients (6 months-4 years) developed carboxyhemoglobinemia after cardiac transplant.
- Elevated carboxyhemoglobin levels (5.5-7.7%) were observed with high-dose sodium nitroprusside (7-16 microg/kg/min).
- No other confounding medications were administered that could explain the elevated levels.
Findings:
- High-dose sodium nitroprusside administration is associated with induced carboxyhemoglobinemia in pediatric cardiac transplant patients.
- The mechanism likely involves the induction of hemeoxygenase.
- One patient experienced a fatal outcome, while three recovered fully after drug discontinuation.
Implications:
- Clinicians should be aware of the risk of carboxyhemoglobinemia when using high-dose sodium nitroprusside in pediatric heart transplant patients.
- Monitoring carboxyhemoglobin levels may be warranted in this specific patient population.
- Further research into the dose-dependent effects and underlying mechanisms is recommended.